NUWE Nuwellis, Inc.

Executive Summary

Nuwellis priced a dilutive emergency capital raise via a 424B4 prospectus supplement, offering up to 1,903,338 shares of common stock (or pre-funded warrants for up to 18,096,662 shares) plus Series C and Series D common warrants at a combined public offering price of $0.30 per unit. The offering is a reasonable best-efforts deal with no minimum, expected to raise up to ~$5.2M net for working capital. The offering price represents a ~30.4% discount to the last closing price of $0.431. This is a certain present dilution event for a company with a $0M market cap, a history of operating losses ($17.5M net loss in FY2025), and only enough cash to fund operations through Q2 2026.

Key Financial Metrics

Actionable Insight

Key Facts

• Offering of up to 1,903,338 shares of common stock (or pre-funded warrants for up to 18,096,662 shares) at $0.30 per unit, with Series C warrants for 60M shares and Series D warrants for 20M shares.
• Public offering price of $0.30 per share and accompanying common warrants represents a ~30.4% discount to the June 4, 2026 closing price of $0.431.
• Estimated net proceeds of ~$5.2M if fully subscribed, with no minimum offering requirement; proceeds used for working capital and general corporate purposes.
• Company had only $2.083M in cash as of March 31, 2026, and stated it had enough cash to fund operations only through Q2 2026.
• Concurrent private transaction to reprice up to 3,284,788 outstanding warrants to $0.30, subject to stockholder approval.
• Placement agent is Ladenburg Thalmann & Co. Inc., receiving 9% cash fee ($540K) and warrants for 600K shares at $0.495.
• Lock-up restrictions apply to officers, directors, and certain stockholders until 15 days after stockholder approval and reverse stock split.

Financial Impact

Up to ~$5.2M net proceeds raised at a ~30.4% discount to market, representing massive dilution: the offering could increase shares outstanding by ~760% (from 2.64M to ~22.64M shares if all pre-funded warrants are exercised).

Risk Factors

• Massive dilution: the offering could increase outstanding shares by ~760% if all pre-funded warrants are exercised.
• No minimum offering amount — the company may raise significantly less than the $5.2M target, leaving it undercapitalized.
• Common warrants are contingent on stockholder approval and a reverse stock split; if not obtained, they have no value.
• Company has a history of operating losses ($17.5M in FY2025), accumulated deficit of $316.3M, and only $2.083M cash as of March 31, 2026.
• Nasdaq delisting risk due to low bid price and proposed enhanced listing standards.
• Concurrent warrant reprice transaction adds further dilution if exercised.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status